Skip to content

PDA+: A Personal Digital Assistant for Obesity Treatment

PDA+: A Personal Digital Assistant for Obesity Treatment

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00371462
Acronym
PDA+
Enrollment
70
Registered
2006-09-04
Start date
2007-10-31
Completion date
2011-09-30
Last updated
2016-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Pain

Keywords

intervention study, technology, weight loss

Brief summary

The purpose of this study is to determine whether including a PDA decision support tool plus distance support enhances the outcomes attainable by the MOVE2! (Managing Obesity for Veterans Everywhere) standard care alone. Primary hypotheses are that obese patients with chronic pain who are randomized to MOVE2! + PDA + Support will a) lose more weight by 6 months, b) show greater maintenance of weight loss at 12 months, and c) display greater reduction in pain intensity and pain-related disability than those randomized to Standard Care. Secondary hypotheses are that MOVE2! + PDA + Support, compared to Standard Care will result in: a) improved quality of life, b) greater treatment adherence, and c) reduced care utilization.

Detailed description

An obesity epidemic is gaining momentum in the U.S. and the VA in particular. Among Veterans receiving care at VA outpatient centers in the year 2000, the prevalence of overweight was 73% and obesity was 33%. Obesity is an expensive condition partly because it contributes to the development of other chronic diseases. In addition to its adverse medical consequences, obesity takes a toll on quality of life. In general and among veterans specifically, obesity is associated with chronic pain conditions. Pain and obesity in combination adversely affect health-related quality of life and increase care utilization. To treat obesity, VA patient services has implemented MOVE! (Managing Obesity for Veterans Everywhere), a nationwide, pre-inpatient, pre-surgical standard of care. MOVE! Level 2 (MOVE2!), the platform for this study, enrolls in group treatment patients who are ready to make behavioral changes in diet and physical activity. The current study interfaces with and adds to MOVE2! treatment in order to maximize utility and sustainability in VA. The intervention in the current study involves provision of a personal digital assistant (PDA), a hand-held computer decision support tool to self-regulate diet and activity along with staff support (via telephone or e-mail per patient's preference). Experimental Design. The current study is a 2-group prospective randomized controlled trial comparing the effects of (1) Standard Care: MOVE2! group weight loss counseling alone and (2) MOVE2! + PDA + Support. Specific aims are to enroll from VA primary care a sample of 150 obese patients who meet study criteria for chronic pain and are ready to make behavioral changes, including enrolling in MOVE2!. Primary outcomes (weight and pain) and secondary outcomes (quality of life, treatment adherence, healthcare utilization) will be measured every 3 months (baseline, treatment months 3 and 6, and follow-up months 9 and 12). Before beginning the current study, we will conduct two types of formative research. Part 1A: We will recruit 15 Veterans who are obese and have chronic pain for the purpose of pilot testing the PDA. Veterans will participate in one focus group before and one after they use the PDA for one week. Part 1B: We will also conduct focus groups with 10 MOVE! personnel and 10 staff who work in Hines Primary Care Clinic to identify perceived needs and barriers regarding implementing our PDA intervention. Objective & Hypotheses. To determine whether the provision of a PDA decision support tool plus distance support enhance the outcomes attainable by the MOVE2! standard care alone. Primary hypotheses are that obese patients with chronic pain who are randomized to MOVE2! + PDA + Support will a) lose more weight by 6 months, b) show greater maintenance of weight loss at 12 months, and c) display greater reduction in pain intensity and pain-related disability than those randomized to Standard Care. Secondary hypotheses are that MOVE2! + PDA + Support, compared to Standard Care will result in: a) improved quality of life, b) greater treatment adherence, and c) reduced care utilization. Data Analysis. Outcomes will be analyzed longitudinally on an intent to treat basis. The general analytic approach will be to use longitudinal mixed-effects regression models implemented via SAS PROC MIXED. Stratification variables (age, BMI, gender) will be included in all analyses.

Interventions

BEHAVIORALUse of PDA + support to reduce weight and pain

participants will attend the MOVE! group, record their food, activity, mood, pain, and weight daily via a PDA. Participants will be assigned a coach to help them set physical activity and calorie goals in order to produce a weight loss of .5%-1% per week on average over the course of 6 months. Participants will continue to log using the PDA during the 2nd 6-months for follow-up. They will also be asked to attend assessments at 3, 6, 9, and 12 months.

BEHAVIORALMOVE! level 2 group weight loss counseling

Participants will attend the MOVE! group and will be asked to complete assessments at 3, 6, 9, and 12 months.

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with BMI \>25 will be recruited from the primary care clinics at Hines Hospital VAMC. Enrollment of patients with this BMI criteria allows comparability with other obesity behavioral treatment trials. The enrollment policy is also consistent with the 2005 VA/DoD Practice Guideline that recommends obesity treatment for all Veterans with BMI \>25. * Male or female Veterans * Age \>18 * With chronic pain (Numeric Rating Scale of pain intensity \[NRS-I\] \> 4 for \> 6 months prior to enrollment) * Ready to make a weight loss effort involving diet and activity change * Able to communicate comfortably in English. * The primary pain complaint must be possibly related to obesity (e.g., back, knee, leg, neck, arm, or full-body pain, and not exclusively headache or cancer-related pain).

Exclusion criteria

* Has an active eating disorder or substance abuse disorder --Participating in another VA-funded research project -Significant cognitive or sensorimotor impairment precluding use of the PDA * Already participating in a structured diet or exercise program or plans to begin such a program outside the study during the next year; requires use of an assistive device for mobility * At risk for adverse cardiovascular events with moderate intensity activity * Plans to relocate within the upcoming year

Design outcomes

Primary

MeasureTime frameDescription
Weight (Measured at Assessment Visits) and Pain Intensity and Pain Related Disability (NRS-I)baseline, 3, 6, 9, and 12 monthsStudy was terminated by VA. No VA outcome data to report.

Countries

United States

Participant flow

Participants by arm

ArmCount
Arm 1
MOVE! level 2 group weight loss counseling, the VA standard of care alone (Standard Care); Use of PDA + support to reduce weight and pain: participants will attend the MOVE! group, record their food, activity, mood, pain, and weight daily via a PDA. Participants will be assigned a coach to help them set physical activity and calorie goals in order to produce a weight loss of .5%-1% per week on average over the course of 6 months. Participants will continue to log using the PDA during the 2nd 6-months for follow-up. They will also be asked to attend assessments at 3, 6, 9, and 12 months.
34
Arm 2
MOVE! level 2 + Personal Digital Assistant decision support tool (PDA) (Treatment) MOVE! level 2 group weight loss counseling: Participants will attend the MOVE! group and will be asked to complete assessments at 3, 6, 9, and 12 months.
35
Total69

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyOther78
Overall StudyWithdrawal by Subject10

Baseline characteristics

CharacteristicArm 2TotalArm 1
Age, Continuous57.7 years
STANDARD_DEVIATION 10.2
57.7 years
STANDARD_DEVIATION 11.9
57.7 years
STANDARD_DEVIATION 13.5
BMI35.8 kg/m2
STANDARD_DEVIATION 3.8
36.3 kg/m2
STANDARD_DEVIATION 4.6
36.9 kg/m2
STANDARD_DEVIATION 5.4
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants4 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
32 Participants65 Participants33 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
8 Participants17 Participants9 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
27 Participants52 Participants25 Participants
Region of Enrollment
United States
35 participants69 participants34 participants
Sex: Female, Male
Female
5 Participants10 Participants5 Participants
Sex: Female, Male
Male
30 Participants59 Participants29 Participants
Waist circumference (cm)120.4 cm
STANDARD_DEVIATION 8.9
120.4 cm
STANDARD_DEVIATION 11.7
120.4 cm
STANDARD_DEVIATION 14
Weight (kg)110.1 kg
STANDARD_DEVIATION 15.1
111.1 kg
STANDARD_DEVIATION 15.6
113.7 kg
STANDARD_DEVIATION 16.1

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 340 / 35
serious
Total, serious adverse events
0 / 340 / 35

Outcome results

Primary

Weight (Measured at Assessment Visits) and Pain Intensity and Pain Related Disability (NRS-I)

Study was terminated by VA. No VA outcome data to report.

Time frame: baseline, 3, 6, 9, and 12 months

Population: No data were analyzed due to termination of the study.

Source: ClinicalTrials.gov · Data processed: Mar 29, 2026